

SYNTHESIS AND PLA₂-INHIBITORY PROPERTIES OF 2(R)-ACETAMIDO-ALKYLPHOSPHOMETHANOLS WITH A VARIABLE AGGREGATE ANCHOR

Jörg T. Kley,^a Günter v. Kiedrowski,^b Clemens Unger,^a and Ulrich Massing ^{*,a}

^a*Tumor Biology Center, Dept. of Clinical Research, Breisacherstr. 117, 79106 Freiburg, Germany*


^b*Institute of Organic Chemistry I, Ruhr-University, 44780 Bochum, Germany*

Received 29 October 1998; accepted 7 December 1998

Abstract: Acylamino inhibitors of 14 kDa-PLA₂ were synthesized which differ in the moiety that is not bound into the enzyme's active site but immersed in the lipid aggregate when a ternary inhibitory complex is formed. Our results indicate that this part of the inhibitors does not significantly influence inhibitory properties as long the amphiphilic character is retained. So, inhibitory and biophysical properties should be variable independently. © 1999 Elsevier Science Ltd. All rights reserved.

Phospholipases A₂ (PLA₂) catalyze the hydrolysis of *sn*-2 fatty acids from membrane glycerophospholipids. Increased activity of human non-pancreatic secretory PLA₂ (hnps PLA₂) has been demonstrated in several inflammatory and non-inflammatory diseases such as rheumatoid arthritis, septic shock, ARDS and neoplastic diseases.^{1–5} Inhibition of hnps PLA₂ may therefore be a promising therapeutic strategy. Acylaminophospholipids are a class of potent substrate analogous inhibitors of hnps PLA₂ and other 14 kDa-PLA₂.^{6–10} They form ternary inhibitory complexes consisting of the enzyme, an inhibitor molecule and the substrate aggregate.¹¹ It is known from X-ray studies that both the polar headgroup and the amide moiety of acylaminophospholipids are bound into the active site of 14 kDa-PLA₂.^{12–14} In contrast, the apolar part of long chain acylaminophospholipids is not completely bound into the enzyme, but is partly immersed in the substrate aggregate when a ternary complex is formed.^{15,16} From the inhibitory properties of acylaminophospholipids and related inhibitors investigated by us¹⁷ and others^{9,10} we concluded that in ternary complexes the apolar parts of 2-acylamino-alkylphospholipids are immersed in the lipid aggregate approximately from the ninth carbon of the alkyl chain up as shown in fig. 1. This is in line with an X-ray structure of hnps PLA₂ complexed with an acetamido-alkylphospholipid inhibitor published by Oh.¹³ To investigate the influence of the moiety of acylaminophospholipids immersed in the lipid aggregate (in the following referred to as aggregate anchor) on PLA₂ inhibition we synthesized a series of 2(R)-acetamido-alkylphosphomethanols with identical enzyme bound part but with aggregate anchors differing in both size and polarity.

Figure 1. General structure of the inhibitors investigated



Chemistry¹⁸

The central steps to synthesize the chiral inhibitors **11b–g** (fig. 3) were Wittig reactions of the respective


* Corresponding author. E-mail: umas@tumorbio.uni-freiburg.de; Fax: +49-761-206-1899

triphenylphosphonium bromides **6a–c**¹⁹ with *N*-Z-*O*-Pv-(*S*)-serinal (**4**), which was prepared from glucosamine (**1**) (fig. 2). Reduction of the anomeric center of **1** with sodium borohydride and subsequent Z-protection of the amino group afforded **2**. After column filtration to remove borates, the primary hydroxyl groups were selectively pivaloylated to afford **3** as a powder in 45 % yield with respect to **1**. In order to avoid racemization, the aldehyde **4** was prepared from **3** by periodate oxidation only immediately before the following Wittig reaction and reacted as crude product without previous chromatographic purification.

Due to the presence of equimolar amounts of pivaloxyloxyacetaldehyde in the crude **4**, two equivalents of the respective triphenylphosphonium bromides **6a–c** had to be applied in the Wittig reactions (fig. 3). Deprotection of the Wittig products **7a–c** was accomplished by acidic cleavage without affecting the benzyl ether in **7a**. The oxazaphospholane intermediates^{20,21}, generated by reacting **8a–c** with methyl dichlorophosphate, were opened with 6 N HCl to afford the zwitterionic phosphomethanols **9a–c**. Acetylation (to give **10a–c**) and hydrogenolysis afforded the inhibitors **11b–d**. The esters **11e–f** were prepared from the alcohol **11d** using the respective acid chlorides.²²


Enantiomeric purity was checked by ¹⁹F NMR spectroscopy. For this purpose, **8c** was hydrogenated to give 2(*R*)-amino-1-octadecanol which was quantitatively reacted with excess Mosher's acid chloride²³ (ee ≥ 98 %).

Figure 2. Synthesis of *N*-Z-*O*-Pv-(*S*)-serinal (**4**)



Discussion

The inhibitors **11b–g** listed in fig. 3 have identical enzyme bound parts, but different aggregate anchors (compare fig. 1). The non-amphiphilic compound **11d** is a poor inhibitor, whereas the inhibitory properties^{24,25} of all other (amphiphilic) compounds are comparable with those of other potent PLA₂ inhibitors.^{6–10,26} This difference is likely due to the accumulation of amphiphilic but not hydrophilic inhibitors in the substrate aggregate, i.e. in the immediate vicinity of the active enzyme. Within the amphiphilic inhibitors (**11a–c,e–f**) both the overall size of the aggregate anchor and the insertion of ester or ether groups into it only marginally affect inhibition. These results imply that biophysical parameters of acylaminophospholipids such as critical micelle concentration (CMC) and hydrophilic-lipophilic balance (HLB) values can be varied by modifying the aggregate anchor without relevantly affecting the inhibitory properties as long as the overall amphiphilic character is

Figure 3. Synthesis and PLA₂-inhibitory properties²⁴ of the 2-acetamido-alkylphosphomethanols **11b–g**

Structure of R	No	IC ₅₀ (μM) ²⁵	X _i (50) ²⁵
	11b	1.7	0.00029
	11c	3.4	0.00057
	11d	350	0.058
	11e	2.3	0.00039
	11f	3.1	0.00052
	11g	5.0	0.00084

retained. As biophysical properties influence pharmacokinetics, it should be possible to combine enhanced inhibitory power (which can be achieved by modifying the enzyme bound moiety of the inhibitors as demonstrated by others^{14,26}) with an adaptation of the pharmacokinetic behavior to different pharmacologic needs by varying size and polarity of the inhibitors' aggregate anchors.

References and Notes

1. Berenbaum, F. *Rev. Rhum. Engl. Ed.* **1995**, *62*, 409.
2. Vadas, P.; Browning, J.; Edelson, J.; Pruzanski, W. *J. Lipid Mediat.* **1993**, *8*, 1.
3. Romaschin, A. D.; et al. *Clin. Biochem.* **1992**, *25*, 55.
4. Ogawa, M. In *Progress in surgery*; Uhl, W.; Nevalainen, T. J.; Büchler, M. W., Eds; Karger: Basel, 1997; Vol. 24, pp. 200-204.
5. Massing, U.; Kraft, A.; Stier, B.; Klose, M.; Unger, C. *Manuscript in preparation*.
6. Bayburt, T.; Yu, B.-Z.; Lin, H.-K.; Browning, J.; Jain, M. K.; Gelb, M. H. *Biochemistry* **1993**, *32*, 573.
7. Jain, M. K.; Tao, W.; Rogers, J.; Arenson, C.; Eibl, H.; Yu, B. *Biochemistry* **1991**, *30*, 10256.
8. van den Berg, L.; Franken, P. A.; Verheij, H. M.; Dijkman, R.; de Haas, G. H. *Biochim. Biophys. Acta* **1992**, *1124*, 66.
9. de Haas, G. H.; et al. *Biochim. Biophys. Acta* **1993**, *1167*, 281.
10. de Haas, G. H.; Dijkman, R.; Ransac, S.; Verger, R. *Biochim. Biophys. Acta* **1990**, *1046*, 249.
11. van den Berg, B.; et al. *J. Biomol. NMR* **1995**, *5*, 110.
12. Thunnissen, M. M. G. M.; et al. *Nature* **1990**, *347*, 689.
13. Oh, B.-H. *Acta Crystallogr. D* **1995**, *51*, 140.
14. Cha, S.-S.; et al. *J. Med. Chem.* **1996**, *39*, 3878.
15. Dennis, E. A. *J. Biol. Chem* **1994**, *269*, 13057.
16. Scott, D. L.; White, S. P.; Otwinowski, Z.; Yuan, W.; Gelb, M. H.; Sigler, P. B. *Science* **1990**, *250*, 1541.
17. Kley, J. T.; Massing, U. *manuscript in preparation*
18. All compounds reported gave spectral data in accord with assigned structures.
19. The educts **5a** and **5b** were prepared according to standard procedures by alkylation of benzylic alcohol or ethylene glycol, respectively.
20. Eibl, H.; *Proc. Natl. Acad. Sci. USA* **1978**, *75*, 4074.
21. Akita, H.; Umezawa, I.; Matsukura, H.; Oishi, T. *Chem. Pharm. Bull.* **1992**, *40*, 318.
22. Cholesteryl oxycarbonylpropionyl chloride was prepared by reaction with thionyl chloride from cholesterol hemisuccinate, the preparation of which is described in: Kley, J. T.; Fichert, Th.; Massing, U. *Chem. Mon.* **1998**, *129*, 319
23. Dale, J. A.; Dull, D. L.; Mosher, H. S. *J. Org. Chem.* **1969**, *34*, 2543.
24. PLA₂ inhibition was determined using a mixed micelles pH-stat assay and 14 kDa-PLA₂ from *Naja mossaambica mossaambica* (acidic isoenzyme, purchased from Sigma) as described previously in: Kley, J. T.; Unger, C.; Massing, U. *Biochim. Biophys. Acta* **1998**, *1392*, 193
25. IC₅₀ values of amphiphilic PLA₂ inhibitors (**11b,c,e-g**) depend on the substrate concentration applied in the assay. To allow comparison of our data with results from others X_i(50) values are given in addition to the IC₅₀ values. $X_i = [\text{inhibitor}] / ([\text{substrate}] + [\text{inhibitor}])$
26. Schevitz, R. W.; et al. *Nature Struct. Biol.* **1992**, *2*, 458.